Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Voyager Therapeutics

Evaluate

Thumbnail
January 09, 2023

JP Morgan 2023 – licensing deal flurry offers limited cash up front

Thumbnail
October 24, 2022

Syncona sets its sights on a gene therapy turnaround

But, with Applied Genetic Technologies Corporation, can lightning strike a third time?

Article image
Vantage logo
March 08, 2022

Voyager’s new focus gets more big pharma validation

Article image
Vantage logo
May 12, 2021

Toxicity concerns send Larimar down

The company hopes that its novel approach in Friedreich’s ataxia could still have legs, but other assets are further ahead.

Article image
Vantage logo
April 19, 2021

Stock market correction sends biopharma back to the start of 2021

Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.

Article image
Vantage logo
January 08, 2021

One victory for biopharma over the coronavirus in 2020

A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.

Article image
Vantage logo
December 23, 2020

Voyager hold adds to gene therapy woes

Article image
Vantage logo
October 06, 2020

Axovant punished for Parkinson’s update

Article image
Vantage logo
February 14, 2020

Upcoming events – Avadel takes on Jazz and Axovant awaits early results

Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.

Article image
Vantage logo
December 20, 2019

Plenty of choice remains for buyers of gene therapy

Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.

Article image
Vantage logo
July 05, 2019

Cannabis, M&A and data spur strong gains among small and midcaps

The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up